KR20240013750A - Ras 돌연변이를 표적으로 하는 t 세포 수용체 및 그의 용도 - Google Patents

Ras 돌연변이를 표적으로 하는 t 세포 수용체 및 그의 용도 Download PDF

Info

Publication number
KR20240013750A
KR20240013750A KR1020237041629A KR20237041629A KR20240013750A KR 20240013750 A KR20240013750 A KR 20240013750A KR 1020237041629 A KR1020237041629 A KR 1020237041629A KR 20237041629 A KR20237041629 A KR 20237041629A KR 20240013750 A KR20240013750 A KR 20240013750A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
sequence shown
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041629A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 에이. 클레바노프
스미타 에스. 찬드란
Original Assignee
메모리얼 슬로안 케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안 케터링 캔서 센터 filed Critical 메모리얼 슬로안 케터링 캔서 센터
Publication of KR20240013750A publication Critical patent/KR20240013750A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A61K39/4611—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
KR1020237041629A 2021-05-25 2022-05-25 Ras 돌연변이를 표적으로 하는 t 세포 수용체 및 그의 용도 Pending KR20240013750A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192783P 2021-05-25 2021-05-25
US63/192,783 2021-05-25
PCT/US2022/030814 WO2022251283A1 (en) 2021-05-25 2022-05-25 T cell receptors targeting ras mutations and uses thereof

Publications (1)

Publication Number Publication Date
KR20240013750A true KR20240013750A (ko) 2024-01-30

Family

ID=84230235

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041629A Pending KR20240013750A (ko) 2021-05-25 2022-05-25 Ras 돌연변이를 표적으로 하는 t 세포 수용체 및 그의 용도

Country Status (11)

Country Link
US (1) US20240091361A1 (https=)
EP (1) EP4347639A4 (https=)
JP (1) JP2024520427A (https=)
KR (1) KR20240013750A (https=)
CN (1) CN117545766A (https=)
AU (1) AU2022283277A1 (https=)
BR (1) BR112023024595A2 (https=)
CA (1) CA3219923A1 (https=)
IL (1) IL308755A (https=)
MX (1) MX2023014073A (https=)
WO (1) WO2022251283A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024039576A2 (en) * 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
AU2024228388A1 (en) * 2023-02-27 2025-10-02 Adaptive Biotechnologies Corp. Therapeutic t cell receptors targeting kras g12d
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
AU2024339041A1 (en) * 2023-09-05 2026-04-16 Bluesphere Bio, Inc. T cell receptors targeting an npm1 neoantigen
WO2025137468A1 (en) * 2023-12-22 2025-06-26 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
US20210147550A1 (en) * 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
CR20200287A (es) * 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
CA3116749A1 (en) * 2018-10-24 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a3-restricted t cell receptors against mutated ras
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
CN114026116A (zh) * 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途

Also Published As

Publication number Publication date
EP4347639A1 (en) 2024-04-10
CN117545766A (zh) 2024-02-09
WO2022251283A1 (en) 2022-12-01
AU2022283277A1 (en) 2023-12-14
IL308755A (en) 2024-01-01
BR112023024595A2 (pt) 2024-02-15
EP4347639A4 (en) 2025-08-06
CA3219923A1 (en) 2022-12-01
US20240091361A1 (en) 2024-03-21
MX2023014073A (es) 2024-02-21
JP2024520427A (ja) 2024-05-24
AU2022283277A9 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
US20240091361A1 (en) T cell receptors targeting ras mutations and uses thereof
US12103956B2 (en) Suicide module compositions and methods
CN113166226A (zh) 表达显性负性fas的免疫应答细胞及其用途
CA3181394A1 (en) Chimeric antigen receptors targeting cd127 and use thereof
JP7822620B2 (ja) 免疫療法のエンハンサーとして有用なｉｌ－１０／ｆｃ融合タンパク質
JP2025061710A (ja) Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用
CN112533629A (zh) 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
US20240285759A1 (en) T cell receptors targeting q61-comprising ras mutations and uses thereof
WO2025006196A1 (en) T cell receptors targeting ras with g12d, g12r, or g12v mutation
US12371467B2 (en) T cell receptors targeting PIK3CA mutations and uses thereof
WO2022166665A1 (zh) 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
KR20250174626A (ko) P53의 y220c 또는 r175h 돌연변이를 표적화하는 t 세포 수용체
KR20240004453A (ko) 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체
CN115279389A (zh) 新型显性负性Fas多肽、包含其的细胞及其用途
WO2025024648A2 (en) T cell receptors targeting tp53 hotspot mutations and uses thereof
HK40070453A (en) T cell receptors targeting pik3ca mutations and uses thereof
WO2024148369A1 (en) Targeted il-12 affinity variants
WO2026046995A1 (en) T cell receptors and uses thereof
JP2025501358A (ja) Ｔ細胞受容体、その製造方法、及び使用
HK40126591A (zh) 通用t细胞和组合物及它们的使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231201

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250519

Comment text: Request for Examination of Application